...
首页> 外文期刊>OncoTargets and therapy >The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients
【24h】

The combination of systemic therapy and locoregional radiotherapy prolongs survival in newly diagnosed metastatic nasopharyngeal carcinoma patients

机译:全身治疗和局部放疗相结合可延长新诊断的转移性鼻咽癌患者的生存期

获取原文
           

摘要

Background: The purpose of this study is to assess the role of locoregional radiotherapy (RT) when used in combination with systemic chemotherapy, for patients with newly diagnosed metastatic nasopharyngeal carcinoma (NPC), in a non-endemic region of northern China. Methods: In total, 611 patients with NPCs were newly diagnosed between June 2011 and June?2016 following visits to our hospital; of these, 32 patients presented with metastasis at initial diagnosis. Among these 32 patients, 29 had single-organ metastasis and 3 had multiple-organ metastasis. All patients were treated with RT for local and regional disease. Results: The median follow-up for all patients was 20 months (range 9–59 months), and median survival was not achieved (some patients had succumbed) at the time of the last follow-up. The 2-year overall survival (OS) rate was 75.2%, and 3-year OS rate was 50.1%. There was a significant difference between patients with single- and multiple-organ metastasis: 2-year OS was 67.5% for single- vs 0% for multiple-organ metastasis ( p =0.039). Patients treated with intensity-modulated RT had a better prognosis than patients treated by conventional RT: 2-year OS was 76.6% for single- vs 44.4% for multiple-organ metastasis (no significant difference was found between the 2 groups, p =0.297). For patients with progression (all were with distant disease progression), the median progression time was 8 months (6–22 months), and the median survival after disease progression was 6 months (2–14 months). Conclusion: For patients with newly diagnosed metastatic NPCs, especially with single-organ metastasis, the addition of RT to systemic chemotherapy improved survival and disease control compared with historical cohort.
机译:背景:本研究的目的是评估局部放疗(RT)与全身化疗联合使用对中国北方非流行地区新诊断为转移性鼻咽癌(NPC)的患者的作用。方法:2011年6月至2016年6月至2016年6月,共收治611例NPC患者。其中,有32例在初诊时出现转移。在这32例患者中,有29例发生了单器官转移,有3例发生了多器官转移。所有患者均接受了局部和区域性疾病的放疗。结果:所有患者的中位随访时间为20个月(9-59个月),上次随访时中位生存期未达到(某些患者已屈服)。 2年总生存(OS)率为75.2%,3年OS为50.1%。单器官转移和多器官转移的患者之间存在显着差异:单器官转移的2年OS为67.5%,多器官转移的2年OS为0%(p = 0.039)。接受调强放疗的患者的预后比接受常规放疗的患者好:单器官移植的两年OS为76.6%,多器官转移为44.4%(两组之间无显着差异,p = 0.297) )。对于进展期患者(所有患者均处于远处疾病进展),中位进展时间为8个月(6至22个月),疾病进展后中位生存期为6个月(2至14个月)。结论:对于新诊断的转移性鼻咽癌患者,特别是单器官转移的患者,与历史队列相比,在全身化疗中增加放疗可改善生存和疾病控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号